health
March 6, 2026
FDA reversals leave investors worrying about the fates of other experimental drugs
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.
TL;DR
- The FDA has recently denied or discouraged applications for at least eight experimental drugs, causing investor concern.
- Reasons for rejection include insufficient evidence, lack of placebo testing, and reliance on biomarkers instead of direct efficacy measurement.
- Companies claim the FDA has reversed its previous guidance, leading to uncertainty about regulatory standards.
- The FDA states it makes decisions based on evidence and conducts rigorous reviews, denying any regulatory uncertainty.
- Recent decisions have left investors questioning whether the FDA's approval bar has changed for other drugs in development.
Continue reading the original article